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depletion during the expansion phase was possible and
resulted in a higher purity of NK cells (56 - 96%). The cells
retained their proliferative capacity after depletion and
expansion factors of 30-156-fold were obtained.
Flow cytometry analysis revealed comparable expression
of CD16, NKp30, NKp46 and NKG2D for manually or auto-
matically expanded NK cells either from CD3-depleted or
undepleted cultures.
Results show that large scale automation of NK cell
expansion is possible by use of the CliniMACS Prodigy. CD3
depletion of unwanted T and NK like T cells during culture is
feasible.170
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Background: Successful vascularized composite allograft
(VCA) transplantation requires life-long treatment
combining more than two immunosuppressive agents and
pose signiﬁcant risks and side effects. Cell based therapies
are a new promising approach for tolerance induction that
could prevent or reduce negative impact of life-long immu-
nosuppression. Bone marrow transplantation has already
been tested for solid organs, face and upper extremity
transplants for modulation of immune responses. We
propose a new cellular therapy based on the ex vivo created
donor-recipient chimeric cells as an alternative approach to
bone marrow based therapies in support of VCA. The aim of
this preclinical study was to create and characterize in vitro
the phenotype, genotype and viability of fused human di-
chimeric cells (dCC).
Materials and Methods: Fourteen ex vivo fusions of human
umbilical cord blood (UCB) cells were performed. Mono-
nuclear cells (MNCs) were isolated from UCB originating
from 2 different donors. Next MNCs were stained separately
by PKH26 and PKH67. Fusion procedure was performed
using polyethylene glycol (PEG) technique. Double PKH26
and PKH67 stained cells were sorted out and subjected to
further assessments. Flow cytometry (FC), (CD3, CD4, CD8,
CD19, CD34 and CD90, viability test), confocal microscopy
(CM), ﬂuorescent lymphocytotoxicity assay (LCT), PCR-
reverse sequence-speciﬁc oligonucleotide probe (PCR-
rSSOP) and short tandem repeat- PCR (STR-PCR) and
colony- forming unit (CFU) assay were assessed to charac-
terize the phenotype and genotype of fused human
chimeric cells.
Results: FC and CM analysis conﬁrmed UCB fusion and
creation of human dCC. Using LCT assay we determined that
human dCC are sharing HLA class I and class II antigens
speciﬁc for both types of UCB donors used for fusion. Results
of the LCT test were conﬁrmed by rSSOP and STR assaywhich
revealed that fused dCC were in fact originating (39-51%)
from each of the UCB donors. After fusion 96-99% of cells
were viable. Preliminary phenotype characterization showed
expression of all assessed markers on the surface of dCC. CFU
assay conﬁrmed the presence and functionality of dCC
mature progenitor comparable to untreated cord blood
progenitor cells.Conclusions: We successfully conﬁrmed feasibility of ex
vivo fusion of UBC cells leading to creation of human
fused dCC. We characterized cell phenotype and viability.
This unique concept of di-chimeric cell therapy introduces
new applications in transplant surgery. The ultimate goal
is to induce tolerance in VCA transplants.171
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To date, despite recent progress in the treatment of
Plasma Cell Myeloma (PCM), it remains an incurable
disease in which prolonged therapy (maintenance)
appears to be beneﬁcial. Th1 immunity is critical in tumor
immune surveillance and immune mediated tumor eradi-
cation, in particular of PCM. Immune reconstitution deﬁ-
ciency following autologous stem cell transplantation
(AHCT) is believed to be a barrier to tumor eradication.
Immunotherapy efforts and attempts to boost immunity
with adoptive cell transfer have been thwarted by the
short life span of the transferred cells. In our pre-clinical
work, we found that human Th1/Tc1 lymphocytes, gener-
ated ex vivo in the presence of rapamycin (“T1.R”), pro-
longed engraftment in a human-into-murine model of
xenogeneic GVHD. Based on these data, we have imple-
mented a phase I, dose escalation clinical trial to evaluate
the feasibility and toxicity of the adoptive transfer of
autologous T1.R lymphocytes following AHCT in subjects
with recurrent or newly diagnosed high-risk PCM.
Subjects are receiving T1.R cells at doses ranging from
1x105 to 45x106 cells/kg. To generate T1.R cells, lympho-
cytes are collected by steady-state apheresis prior to
hematopoietic progenitor cell mobilization/collection;
elutriated lymphocytes are then cultured for 6 days using
CD3, CD28 co-stimulation, polarizing cytokines (IL-2 + IFN-
alpha), and high-dose rapamycin (1 mmol) and adminis-
tered 6-8 weeks following AHCT. T1.R cells were generated
in all cases (n¼13); eight subjects have safely received
T1.R cells at a median of 55 days post-AHCT. There have
been no clinical adverse events attributable to the T1.R
cells, and there has been no post-infusion serum elevation
of the following cytokines tested at 1h, 4h, 24h, 48h, 72h
and 7, 14 and 28 days: GM-CSF, INF-g, IL-1b, IL-6, IL-8 and
TNF-a. Current accrual is proceeding at the 5 x 106 cells/
kg cohort. T1.R cell recipients have in general shown
a disease response (see Table), although the median post-
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S198T1.R follow-up is only 137 days. In conclusion, autologous
T1.R cells can be generated and appear safe to infuse at
evaluated doses after AHCT in patients with PCM.Table
UPN Age Sex Disease;
Status pre
T1.R
T1.R dose
(x106/kg)
Disease
Status post
T1.R
F/U
post
T1.R
(days)
2 36 F l chain;
refractory;
CR
0.1 PD at d180 347
3 58 F l chain;
recurrent;
VGPR
3.0 PD at d28 187
5 41 F IgG l;
refractory;
SD
0.5 VGPR 257
6 66 F IgG l;
refractory;
PR
1.0 Continuing
PR
221
7 36 F IgG l;
refractory;
VGPR
5.0 Continuing
VGPR
137
8 62 F IgG l,
refractory;
PR
5.0 Continuing
PR
39
9 71 M IgG k, high-
risk; VGPR
5.0 CR 102
10 36 M IgA k, high-
risk; CR
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Insulin-Like Growth Factor 1 Mitigates Hematopoietic
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We have previously demonstrated that mitigation of
lethal irradiation by growth hormone is associated with
an increase of insulin-like growth factor 1 (IGF-1) level
in blood, suggesting that IGF-1 may be able to mitigate
against lethal irradiation. In this study, we tested this
possibility directly. BALB/c mice ﬁrst received 7.5 Gy of
total body radiation. Within one hour after irradiation,
the mice were then treated with IGF-1 at a dose of 100
mg/dose, i.v., once a day for 5 consecutive days. In the
saline control group, 2 out of 20 mice (10%) survived
more than 100 days after irradiation. By contrast, 8 out
of 20 mice (40%) in the IGF-1-treated group survived
more than 100 days after irradiation (P < 0.01). A single
dose of IGF-1 (500 mg) given within one hour after
irradiation was as effective as the 5-day dose. IGF-1
remained effective when the treatment was delayed for
at least up to 6 hours post irradiation. Moreover, the
radio-protective effect of IGF-1 was still evident when
higher dose of radiation (8.5 Gy, LD100/30) was used.Similar effects were also observed in a second strain of
mice (C57BL/6). Because hematopoietic system is most
sensitive to total body irradiation, we next sought to
determine the effects of IGF-1 on hematopoietic recovery.
Compared with the saline control group, treatment with
IGF-1 signiﬁcantly accelerated the recovery of both
platelets and red cells in blood in irradiated (7.5 Gy)
BALB/c mice when measured at day +14 post irradiation.
Numbers of total bone marrow cells as well as hemato-
poietic stem cells and progenitors per femur were
signiﬁcantly increased in IGF-1-treated mice compared
with the control group. Using ﬂow cytometric analysis
and a novel single cell assay, we demonstrated that IGF-1
protected both hematopoietic stem cells and progenitors
from radiation-induced apoptosis and cell death. Using
an in vitro culture system, we also demonstrated that
IGF-1 was able to facilitate the proliferation and differ-
entiation of non-irradiated and irradiated hematopoietic
progenitors but not stem cells. These data indicate that
IGF-1 mitigates against lethal irradiation through pro-
tecting hematopoietic stem/progenitor cells from radia-
tion-induced apoptosis and also through enhancing
proliferation and differentiation of surviving hematopoi-
etic progenitor cells.POSTER SESSION 1: IMMUNE RECONSTITUTION173
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Higher absolute lymphocyte count at day 30 (ALC 30)
after allogeniec hematopoietic stem cell transplant (HSCT)
has been associatedwith better overall survival (OS). This has
largely been evaluated in small retrospective studies with
cyclosposrine and methotrexate for graft vs. host disease
(GVHD) prophylaxis. ALC 30 and its impact on patient (pt)
outcomes after tacrolimus (Tac) and mycophenolate mofetil
(MMF) is largely unknown.
We retrospectively evaluated a cohort of 414 consecu-
tive pts between January 2005 and June 2010 at Karmanos
Cancer Center. Patients with GVHD or death before day 30
post transplant were excluded from the analysis (N ¼33).
We performed a multivariate logistic regression analysis to
determine donor/recipient predictors of ALC 30. Cox
proportional hazard models were used to assess the
